Partnering

Biothera is seeking licensees and collaborative Research & Development agreements for the commercialization of Imprime PGG in combination with:

  • Anti-tumor monoclonal antibodies for the treatment of various cancers.
  • Growth factors for enhancing hematopoietic activity.
  • Antibiotics for the treatment of infectious disease.

Contact:

 

Steve Smith

Vice President, Business Development

Pharmaceutical Group

ssmith@biothera.com

Direct: 651.256.4626

Mobile: +44 7815 324177


Site design by Checkerboard